AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 273: H1317-H1323, 1997;
0363-6135/97 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez, J. J.
Right arrow Articles by Simons, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, J. J.
Right arrow Articles by Simons, M.

AJP - Heart and Circulatory Physiology, Vol 273, Issue 3 1317-H1323, Copyright © 1997 by American Physiological Society

ARTICLES

Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response

J. J. Lopez, R. J. Laham, J. P. Carrozza, M. Tofukuji, F. W. Sellke, S. Bunting and M. Simons
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

Vascular endothelial growth factor (VEGF) has been utilized to improve blood flow in the setting of myocardial or peripheral vascular ischemia. In this investigation we studied the hemodynamic effects of intracoronary VEGF administration. Hemodynamic parameters and Doppler flow wire recordings from the left anterior descending coronary artery were measured after intracoronary infusion of VEGF (1, 10, and 100 micrograms) in 28 intubated pigs. Additional studies were performed using an in vitro isolated microvessel preparation. VEGF produced a highly significant dose-dependent increase in coronary blood flow (maximal 3.51 +/- 0.85-fold) in the absence of significant changes in epicardial artery diameter, a decline in mean arterial pressure (maximal 43%), and a decrease in left ventricular end-diastolic pressure (maximal 52%), all of which could be inhibited by pretreatment with NG-nitro-L-arginine. The increase in coronary flow seen with 10 or 100 micrograms VEGF was significantly greater than the maximal vasodilation achieved with serotonin or nitroglycerin and was equivalent to a maximal adenosine response. In summary, VEGF stimulates nitric oxide (NO)-dependent dilation of coronary microvessels, and repeat administrations of VEGF resulted in rapid development of tachyphylaxis to VEGF as well as serotonin, but not to nitroglycerin or adenosine, which appeared to be secondary to impaired NO production.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Voisine, A. Rosinberg, J. J. Wykrzykowska, Y. Shamis, G. F. Wu, E. Appelbaum, J. Li, F. W. Sellke, D. Pinto, C. M. Gibson, et al.
Skin-derived microorgan autotransplantation as a novel approach for therapeutic angiogenesis
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H213 - H219.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. R. Grover, T. A. Parker, N. E. Markham, and S. H. Abman
rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L315 - L321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Ashrafpour, N. Huang, P. C. Neligan, C. R. Forrest, P. D. Addison, M. A. Moses, R. H. Levine, and C. Y. Pang
Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H946 - H954.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. W. Sellke and M. Ruel
Vascular growth factors and angiogenesis in cardiac surgery
Ann. Thorac. Surg., February 1, 2003; 75(2): S685 - 690.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. A. Jackson, S. J. Boffey, P. J. Valentine, J. O. Curwen, H. L. Musgrove, et al.
ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration
Cancer Res., August 15, 2002; 62(16): 4645 - 4655.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. Khurana, J. F. Martin, and I. Zachary
Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism
Hypertension, November 1, 2001; 38(5): 1210 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M.-H. Liu, H.-K. Jin, H. S. Floten, Q. Yang, A. P. C. Yim, A. Furnary, T. F. Zioncheck, S. Bunting, and G.-W. He
Vascular Endothelial Growth Factor-Mediated Endothelium-Dependent Relaxation Is Blunted in Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 473 - 477.
[Abstract] [Full Text]

Home page
 CirculationHome page
M. Simons, R. O. Bonow, N. A. Chronos, D. J. Cohen, F. J. Giordano, H. K. Hammond, R. J. Laham, W. Li, M. Pike, F. W. Sellke, et al.
Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus : An Expert Panel Summary
Circulation, September 12, 2000; 102 (11): e73 - e86.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
Y. Feng, J.-H. Yang, H. Huang, S. P. Kennedy, T. G. Turi, J. F. Thompson, P. Libby, and R. T. Lee
Transcriptional Profile of Mechanically Induced Genes in Human Vascular Smooth Muscle Cells
Circ. Res., December 3, 1999; 85(12): 1118 - 1123.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online